A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment









 中文 EN

ACADEMIC HISKY

MAFLD Assessment of liver health Viral hepatitis Liver Cancer and Cirrhosis Evaluate the efficacy of medication Others

A 3-year follow-up of patients with serum HBeAg-positive chronic hepatitis B after 48 to 72 week pegylated interferon α-2a treatment

Wang YZ, Zhang WQ, et al. J Prac Hepatol. 2022:26(5).

Objective

•The aim of this study was to investigate the 3-year follow-up results of patients with serum HBeAg-positive chronic hepatitis B (CHB) after 48 to 72 week pegylated interferon α-2a (peg-IFN α-2a) treatment.

Methods

•A total of 172 Ag-positive treatment-naive CHB patients were enrolled. All patients were treated with peg-IFN α-2a, including 33 patients in group A and 39 patients in group B for 48 weeks and 72 weeks, respectively.
•Liver stiffness measurement (LSM) was performed using FibroTouch transient elastography.

Figures & Tables

Results

•At 48 weeks, 72 weeks of treatment, and 2 and 3 years of follow-up, the LSM of group B were (7.9 ± 1.2) kPa, (7.0 ± 0.9) kPa, (6.8 ± 1.3) kPa, and (6.4 ± 1.8) kPa, respectively, while those of group A were (7.9 ± 1.0) kPa, [(7.5 ± 0.8) kPa, respectively]. P < 0.05], (7.0 ± 1.2) kPa and (6.5 ± 1.2) kPa.
•At the end of follow-up, 52 CHB patients had serum HBeAg seroconversion, and 20 CHB patients did not have.
•There were significant differences in age, treatment duration and baseline HBeAg levels between the response and non-response groups (P < 0.05). Multivariate logistic regression analysis showed that they were all independent influencing factors for serum HBeAg seroconversion (P < 0.05).

Conclusion

•The prolongation of antiviral course of peg-IFN α-2a might improve the clinicalefficacy, and the regimen has a good safety and could enhance the anti-hepatic fibrosis ability.

If you need more academic materials, please contact us.